Shopping Cart 0
Cart Subtotal
AED 0

Caladrius Biosciences Inc (CLBS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a clinical-stage biopharmaceutical company that develops cell therapy products. The company offers multiple technology platforms targeting cardiovascular indications and autoimmune diseases. The company's lead product CLBS03 is an autologous ex vivo polyclonal T regulatory cell clinical phase 2 therapy used in the treatment of type 1 diabetes mellitus. Its other product candidates include CLBS12 used in the treatment of critical limb ischemia; and CLBS14 used in the treatment of coronary microvascular dysfunction. The company offers T regulatory technology and CD34 technology. Caladrius serves biotechnology, pharmaceutical and medical product companies, and academic research institutions. The company operates in Basking Ridge, Irvine and New York, the US. Caladrius is headquartered in Basking Ridge, New Jersey, the US.

Caladrius Biosciences Inc (CLBS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 11

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Caladrius Biosciences Enters into Development Agreement with Sanford Research 14

Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 15

NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 16

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 17

Licensing Agreements 19

Caladrius Biosciences Enters into Licensing Agreement with Shire 19

Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 20

AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 21

SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 22

NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 23

NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 24

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 26

Equity Offering 27

Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 27

Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 28

Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 29

Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 31

Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 33

Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 34

NeoStem Raises USD29 Million in Public Offering of Shares 35

NeoStem to Raise USD30 Million in Private Placement of Shares 36

NeoStem Completes Public Offering Of Shares For USD 40.25 Million 37

NeoStem Files Registration Statement For Private Placement Of Shares For USD 8 Million 38

NeoStem Completes Public Offering Of Shares For USD 11.5 Million 39

NeoStem Completes Private Placement Of Common Stock For USD 3 Million 40

NeoStem Completes Public Offering Of Units For USD 6.8 Million 42

Acquisition 44

Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 44

Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 45

NeoStem Acquires California Stem Cell 46

NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For USD 12 Million 48

Caladrius Biosciences Inc-Key Competitors 49

Caladrius Biosciences Inc-Key Employees 50

Caladrius Biosciences Inc-Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Recent Developments 52

Financial Announcements 52

Aug 09, 2018: Caladrius Biosciences reports 2018 second quarter and first six months financial results 52

May 10, 2018: Caladrius Biosciences Reports 2018 First Quarter Financial Results 54

Mar 22, 2018: Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results 55

Nov 09, 2017: Caladrius Biosciences Reports 2017 Third Quarter Results 57

Aug 10, 2017: Caladrius Biosciences Reports 2017 Second Quarter Results 59

May 15, 2017: Caladrius Biosciences Announces 2017 First Quarter Financial Results 61

Mar 17, 2017: Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results 63

Other Significant Developments 65

Jul 02, 2018: Dr. Marilyn Glassberg Presents Findings on Stem Cell Treatments for Lung Diseases 65

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Caladrius Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 11

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Caladrius Biosciences Enters into Development Agreement with Sanford Research 14

Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 15

NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 16

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 17

Caladrius Biosciences Enters into Licensing Agreement with Shire 19

Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 20

AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 21

SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 22

NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 23

NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 24

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 26

Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 27

Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 28

Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 29

Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 31

Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 33

Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 34

NeoStem Raises USD29 Million in Public Offering of Shares 35

NeoStem to Raise USD30 Million in Private Placement of Shares 36

NeoStem Completes Public Offering Of Shares For USD 40.25 Million 37

NeoStem Files Registration Statement For Private Placement Of Shares For USD 8 Million 38

NeoStem Completes Public Offering Of Shares For USD 11.5 Million 39

NeoStem Completes Private Placement Of Common Stock For USD 3 Million 40

NeoStem Completes Public Offering Of Units For USD 6.8 Million 42

Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 44

Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 45

NeoStem Acquires California Stem Cell 46

NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For USD 12 Million 48

Caladrius Biosciences Inc, Key Competitors 49

Caladrius Biosciences Inc, Key Employees 50

Caladrius Biosciences Inc, Other Locations 51

Caladrius Biosciences Inc, Subsidiaries 51

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Caladrius Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a clinical-stage biopharmaceutical company that develops cell therapy products. The company offers multiple technology platforms targeting cardiovascular indications and autoimmune diseases. The company's lead product CLBS03 is an autologous ex vivo polyclonal T regulatory cell clinical phase 2 therapy used in the treatment of type 1 diabetes mellitus. Its other product candidates include CLBS12 used in the treatment of critical limb ischemia; and CLBS14 used in the treatment of coronary microvascular dysfunction. The company offers T regulatory technology and CD34 technology. Caladrius serves biotechnology, pharmaceutical and medical product companies, and academic research institutions. The company operates in Basking Ridge, Irvine and New York, the US. Caladrius is headquartered in Basking Ridge, New Jersey, the US.

Caladrius Biosciences Inc (CLBS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 11

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Caladrius Biosciences Enters into Development Agreement with Sanford Research 14

Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 15

NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 16

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 17

Licensing Agreements 19

Caladrius Biosciences Enters into Licensing Agreement with Shire 19

Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 20

AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 21

SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 22

NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 23

NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 24

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 26

Equity Offering 27

Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 27

Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 28

Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 29

Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 31

Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 33

Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 34

NeoStem Raises USD29 Million in Public Offering of Shares 35

NeoStem to Raise USD30 Million in Private Placement of Shares 36

NeoStem Completes Public Offering Of Shares For USD 40.25 Million 37

NeoStem Files Registration Statement For Private Placement Of Shares For USD 8 Million 38

NeoStem Completes Public Offering Of Shares For USD 11.5 Million 39

NeoStem Completes Private Placement Of Common Stock For USD 3 Million 40

NeoStem Completes Public Offering Of Units For USD 6.8 Million 42

Acquisition 44

Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 44

Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 45

NeoStem Acquires California Stem Cell 46

NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For USD 12 Million 48

Caladrius Biosciences Inc-Key Competitors 49

Caladrius Biosciences Inc-Key Employees 50

Caladrius Biosciences Inc-Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Recent Developments 52

Financial Announcements 52

Aug 09, 2018: Caladrius Biosciences reports 2018 second quarter and first six months financial results 52

May 10, 2018: Caladrius Biosciences Reports 2018 First Quarter Financial Results 54

Mar 22, 2018: Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results 55

Nov 09, 2017: Caladrius Biosciences Reports 2017 Third Quarter Results 57

Aug 10, 2017: Caladrius Biosciences Reports 2017 Second Quarter Results 59

May 15, 2017: Caladrius Biosciences Announces 2017 First Quarter Financial Results 61

Mar 17, 2017: Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results 63

Other Significant Developments 65

Jul 02, 2018: Dr. Marilyn Glassberg Presents Findings on Stem Cell Treatments for Lung Diseases 65

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Caladrius Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 11

Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Caladrius Biosciences Enters into Development Agreement with Sanford Research 14

Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 15

NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 16

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 17

Caladrius Biosciences Enters into Licensing Agreement with Shire 19

Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 20

AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 21

SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 22

NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 23

NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 24

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 26

Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 27

Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 28

Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 29

Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 31

Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 33

Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 34

NeoStem Raises USD29 Million in Public Offering of Shares 35

NeoStem to Raise USD30 Million in Private Placement of Shares 36

NeoStem Completes Public Offering Of Shares For USD 40.25 Million 37

NeoStem Files Registration Statement For Private Placement Of Shares For USD 8 Million 38

NeoStem Completes Public Offering Of Shares For USD 11.5 Million 39

NeoStem Completes Private Placement Of Common Stock For USD 3 Million 40

NeoStem Completes Public Offering Of Units For USD 6.8 Million 42

Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 44

Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 45

NeoStem Acquires California Stem Cell 46

NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For USD 12 Million 48

Caladrius Biosciences Inc, Key Competitors 49

Caladrius Biosciences Inc, Key Employees 50

Caladrius Biosciences Inc, Other Locations 51

Caladrius Biosciences Inc, Subsidiaries 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Caladrius Biosciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.